摘要
目的探讨阿托伐他汀对急性脑梗死(acute cerebral infarction,ACI)患者氧化应激指标及颈动脉斑块的影响。方法随机将60例ACI患者分为对照组30例和加用阿托伐他汀治疗的治疗组30例。所有患者均给予常规治疗。治疗组在以上治疗的基础上给予阿托伐他汀口服(20mg,每晚1次),连续服用6个月。检测60例ACI患者入院时、治疗1个月后、治疗6个月后的血清中氧化低密度脂蛋白(ox-LDL)、丙二醛(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)水平及颈动脉斑块的变化。结果两组入院第1天检测血清中氧化物及抗氧化酶水平差异无统计学意义(P>0.05),治疗组治疗1个月后、治疗6个月后均较对照组血清中氧化物水平明显降低,治疗1个月、6个月后,治疗组中ox-LDL(493±172)μg/L、(403±171)μg/L,对照组分别为ox-LDL(753±197)μg/L、(723±196)μg/L;治疗组MDA(5.38±0.79)mmol/L、(3.89±0.83)mmol/L,对照组MDA(7.68±0.85)mmol/L、(7.35±0.78)mmol/L(P<0.05);抗氧化酶水平明显升高,治疗组SOD(119.8±13.8)kU/L、(145.2±16.1)kU/L,对照组SOD(95.8±15.2)kU/L、(114.7±15.8)kU/L;治疗组GSH-Px(122.1±13.3)mg/L、(148.7±12.3)mg/L,对照组GSH-Px(98.6±15.3)mg/L、(120.5±15.1)mg/L(P<0.05)。两组入院第1天检测颈动脉内中膜厚度(carotidintimal medial thickness,CIMT)比较差异无统计学意义(P>0.05),治疗组治疗6个月后较对照组颈动脉内中膜厚度(CIMT)明显减小,(1.09±0.12)mm vs(1.63±0.11)mm、治疗组Crouse积分较对照组显著改善,(2.87±1.17)分vs(3.80±1.23)分(P<0.05)。治疗组疗效明显优于对照组(P<0.05)。结论阿托伐他汀能显著减少ACI的氧化应激损伤、改善预后,还可减缓动脉粥样硬化的发展,减轻动脉内膜增厚。
Objective To explore the influence of atorvastatin to oxidative stress mechanism and carotid arterial plaques in acute cereal infarction（ACI） patients. Methods Sixty ACI patients were divided into two groups at random： control group and treatment group. All cases were given routine therapy, the patients in treatment group on the basis of the above treatment were given atorvastatin calcium （20 mg orally once per night） for 6 months. TwO oxidative products, oxidized low density lipoprotein （ox-LDL） and malondialdehyde （MDA）, two antioxidative enzymes, superoxide dismutase（SOD） and glutathione peroxidase（GSH-Px） and carotid arterial ultrasound in 60 ACI patients were detected at admission,1 month and 6 months after treatment. Results All items had no statistical difference at admission to hospital between two groups（ P 〉0.05）. Oxidative products reduced and antioxidative enzymes increased dramatically after 1 month and 6 months treatment in treatment group（ P 〈0.05）. In treatment group after therapy for 1 month and 6 months,oxLDL was （493±172） μg/L and （403±171） μg/L,while in control group oxLDL was （753±197）μg/L and （723±196） μg/L;MDA in treatment group was （5.38±0.79） mmol/L and （3.89±0.83） mmol/L,while that in control was （7.68±0.85） mmol/L and （7.35±0.78） mmol/L. SOD in treatment group was （119.8±13.8） kU/L and （145.2±16.1） kU/L,while that in control group was （95.8±15.2） kU/L and （114.7±15.8） kU/L;GSH-Px in the two groups was （122.1±13.3） mg/L and （148.7±12.3） mg/L,where that in control group was（98.6±15.3） mg/L and （120.5 ~ 15.1） mg/L. Carotid intimal medial thickness and crouse scores were improved, too （ P 〈0.05）. In treatment group after therapy for 6 months,CIMT was （1.09±0.12） mm,while that in control group was （1.63± 0.11） mm;Crouse scores in treatment group were （2.87 ±1.17） scores, while those in control group were （3.80 ± 1.23） scores. The treatment evaluation of treatment group was also much better than that of control group（ P 〈0.05）.Conclusion Atorvastatin calcium could reduce oxidative stress injury and improve the prognosis of ACI, it could alleviate atherosclerosis and lessen endarterium thickening.
出处
《临床荟萃》
CAS
2013年第7期749-752,共4页
Clinical Focus
